SensiGen Gains $300K in VC Cash to Develop, Sell Its PCR and Mass-Spec-Based Dx Tool | GenomeWeb
NEW YORK (GenomeWeb News) — Molecular Diagnostics company SensiGen has received a $300,000 investment from Delaware Crossing Investor Group, a mid-Atlantic-based group of angel investors.
 
SensiGen, based in Ann Arbor, Mich., said it plans to use the funds to develop and sell its AttoSense molecular diagnostic technology, which blends PCR and mass spectrometry to locate biomarkers.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.